The Immunocompromised and COVID-19: An Unwelcome Relationship
Hello, dear readers! Welcome to the rollercoaster that is our relationship with COVID-19—seems like we’re just not ready to break up, are we? Now, let’s dive into the peculiar world of the immunocompromised, who, as we know, are the superheroes of vulnerability.
You see, immunocompromised patients are like that friend who always gets ill at the most inconvenient times. You can go out for a night of debauchery, eat questionable street food, and find yourself as fit as a fiddle, while they just breathe in pollen and boom—sneeze city, population: them. According to our dear friends at the CDC, these heroes (or dare I say, unfortunate souls?) face a higher risk of serious COVID-19 complications. We’re talking hospitalization, ICU admission, mechanical ventilation—basically all the fun activities most of us are trying to avoid!
Who’s on the Immunocompromised VIP List?
So, who exactly falls into this crowded realm of immunity suppression? Grab your popcorn, because the list is a doozy! We have patients battling hematological malignancies, those who’ve undergone CAR-T therapies (no, not the snazzy car rental), and even those who’ve had solid organ transplants. And it doesn’t stop there—enter stage right: folks with multiple sclerosis, autoimmune diseases, and also those with solid neoplasias and certain infections like HIV. If you thought your relatives had a complicated family tree, well, this takes the cake!
The Stats Are Enough to Make You Choke on Your Angular Monitors
Now, here’s the kicker: although immunosuppressed individuals make up just 3.9% of the population, they account for an astonishing 22% of hospitalizations, 28% of ICU visits, and 24% of COVID-19-related deaths. Honestly, if numbers could cry, these would be sobs of an injustice!
Here’s a wild statistic for you: vaccinated patients with hematological malignancies are 10.25 times more likely to succumb to COVID-19 than the average Joe on the street. How’s that for peak unfairness? It’s like being at an amusement park where everyone else is flying high on the rollercoaster while you’re stuck on the kiddie ride, just trying to eat your cotton candy without being blown away by the sheer force of reality.
Why the Long COVID-faced Frowny? Viral Persistence!
Immunosuppression also allows SARS-CoV-2 to have its little viral party extended. These patients often experience greater viral persistence—meaning, the virus likes hanging out longer than invited, making a mess of the place and, oh yes, leading to new variants! Who knew that bad Alex Reed behavior could lead to mutations worthy of a sci-fi novel? For heaven’s sake, even viruses have poor manners these days!
Let’s Wrap This Up, Shall We?
To put a cherry on top of this delightful sundae of immunocompromised consequences, timely identification of these patients can lead to a better approach to managing COVID-19 when it strikes. It’s like having a superhero team on speed dial when the villain rears its ugly head. Identifying at-risk populations early could significantly reduce the risk of severe disease and allow for proactive management, rather than reactive chaos.
So, while we continue to navigate the wacky world of COVID-19, let’s keep our immunocompromised friends close (but not too close, you know, virus and all). They deserve all the attention, protection, and, dare I say, a little extra love! Because if we’ve learned anything from this pandemic, it’s that we’re all in this together. And that, my friends, is a lesson worth holding onto.
Patients with weakened immune systems are particularly susceptible to viral respiratory infections. This heightened vulnerability extends to their immune response after vaccination, which is often markedly lower than that of the general population, leaving them at a significant risk of severe illness.
Specifically concerning COVID-19, the Centers for Disease Control and Prevention (CDC) identifies immunosuppression as a critical risk factor for experiencing disastrous health outcomes, which may include hospitalization, admission to intensive care units, the necessity for mechanical ventilation, or even fatalities.
Which immunocompromised patients are at higher risk of developing severe COVID-19? This includes individuals diagnosed with hematological malignancies, particularly those undergoing CAR-T or hematopoietic stem cell transplantation (HSCT) therapies. It also encompasses patients who have received solid organ transplants, as well as those diagnosed with multiple sclerosis, various autoimmune diseases, solid malignancies, primary immunodeficiencies, or HIV. These groups are particularly vulnerable, facing compounded risks due to their medical conditions and treatments.
Despite constituting only 3.9% of the overall population, immunocompromised patients have alarmingly high hospitalization rates, accounting for 22% of COVID-related admissions. Furthermore, they represent 28% of intensive care unit patients and 24% of all COVID-19-related deaths. Notably, vaccinated individuals with hematological cancers face a staggering 10.25-fold increase in risk of death from COVID-19 when compared to the general populace.
Moreover, prolonged immunosuppression may lead to extended COVID-19 viral persistence. Those infected with SARS-CoV-2, the virus that causes COVID-19, are at an elevated risk of developing severe COVID-19 manifestations. This situation can delay the appropriate treatment for their existing health conditions while simultaneously increasing the likelihood of viral mutations, giving rise to new strains and variants that pose further public health challenges.
Given these compelling factors, the timely identification and management of immunocompromised patients is vital. Early intervention can improve outcomes and substantially decrease the risk of progression to severe COVID-19, ultimately protecting this vulnerable group from potentially dire consequences.
References:
- Respiratory Viruses and People with Weakened Immune Systems. Updated on: March 1, 2024. Available in: Last access: September 2024.
- Dropulic LK, Lederman HM. Overview of Infections in the Immunocompromised Host. Microbiol Spectr. 2016;4(4):10.1128/microbiolspec.DMIH2-0026-2016
- Wilson Dib R, et al. Respiratory Viral Infections in Recipients of Cellular Therapies: A Review of Incidence, Outcomes, Treatment, and Prevention. Open Forum Infect Dis. 2023;10(4):ofad166.
- Lee ARYB, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and metaanalysis. BMJ. 2022;376:e068632.
- Galmic S, et al. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review. Clin Microbiol Infect. 2022;28(2):163-177.
- Singson JRC, et al. Factors Associated with Severe Outcomes Among Immunocompromised Adults Hospitalized for COVID-19 – COVID-NET, 10 States, March 2020-February 2022.MMWR Morb Mortal Wkly Rep. 2022;71(27):878-884.
- Centers for Disease Control and Prevention. Underlying medical conditions associated with higher risk for severe COVID: information for healthcare professionals. Updated on July 30, 2024. Available in: Last access: September 2024.
- Vo AD, et al. Factors Associated With Severe COVID-19 Among Vaccinated Adults Treated in US Veterans Affairs Hospitals. JAMA Netw Open. 2022;5(10):e2240037.
- Evans RA, et al. Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study. Lancet Reg Health Eur. 2023;35:100747.
- Nab L, et al. OpenSAFELY Collaborative. Changes inCOVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform. Lancet Public Health. 2023;8(5):e364-e377.
- Arayici ME, et al. The impact of cancer on the severity of disease in patients affected with COVID-19: an umbrella review and meta-meta-analysis of systematic reviews and meta-analyses involving 1,064,476 participants. in Exp Med.2023;23(6):2221-2229.
- Salmanton-García J, et al. Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022. EClinicalMedicine.2024;71:102553.
- Bertini CD Jr, et al. Coronavirus Disease-2019 in the Immunocompromised Host. Infect Dis Clin North Am. 2024;38(1):213-228.
- Wang L, et al. COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research. Blood Rev. 2022;54:100931.
- Kang SW, et al. Characteristics and risk factors of prolonged viable virus shedding in immunocompromised patients with COVID-19: a prospective cohort study. J Infect. 2023;86(4):412-414.
- Marques AD, et al. SARS-CoV-2 evolution during prolonged infection in immunocompromised patients. mBio. 2024;15(3):e0011024.
- Corey L, et al. SARS-CoV-2 Variants in Patients with Immunosuppression. N Engl J Med. 2021;385(6):562-566.
- Garcia-Vidal C, et al. Prolonged viral replication in patients with hematologic malignancies hospitalized with COVID-19. Haematologica. 2022;107(7):1731-1735.
- Machkovech HM, et al. Persistent SARS-CoV-2 infection: significance and implications. Lancet Infect Dis.2024;24(7):e453-e462.
- Cesaro S, et al. Update of recommendations for the management of COVID-19 inpatients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9). Leukemia. 2023;37(9):1933-1938.
#covid #covidgrave #fightagainstcovid #Pfizercollaboration
